文献速递肿瘤 PET/CT核素与放射性配体治疗

前列腺癌诊疗一体化的现状

Current status of theranostics in prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-12-28

本综述评估了以前列腺特异性膜抗原(PSMA)为靶点的诊疗一体化在前列腺癌(PC)患者中的现状,重点讨论68Ga-PSMA PET显像在初诊和复发分期中的价值以及不断发展的PSMA放射性配体治疗(PRLT)在去势抵抗性前列腺癌(CRPC)中的作用。综述基于现有文献(多为回顾性研究)得出结论:PSMA靶向诊疗一体化在PC诊断和治疗中具有重要临床影响,并推荐68Ga-PSMA PET/CT用于高危患者初诊分期(联合盆腔mpMR)及所有患者二次分期,PSMA靶向治疗是其他治疗方案失败后CRPC患者的有效策略。

要点

  • 68Ga-PSMA PET/CT对高危PC初诊分期有意义,联合盆腔mpMR对患者管理影响最大。
  • 生化复发患者中,PET/CT阳性率与PSA升高直接相关:PSA≤0.5 ng/ml时约50%,PSA>1 ng/ml时≥90%。
  • 177Lu-PSMA配体累积活度30-50 GBq似乎临床安全,约75%患者出现生化缓解和PERCIST/RECIST缓解,5-10%患者出现口干症作为唯一显著副作用。

核心结论

  • 基于当前文献,PSMA靶向诊疗一体化在前列腺癌患者的诊断和治疗中具有重要临床影响。
  • 推荐在高危患者初诊分期时行68Ga-PSMA PET/CT联合盆腔mpMR,并在所有患者二次分期时行68Ga-PSMA PET/CT。
  • 推荐PSMA靶向治疗作为其他治疗方案失败后CRPC患者的有效策略。
  • PSMA靶向治疗与现有治疗模式(如223Ra-氯化物或雄激素剥夺治疗)的联合需要探索,且需要前瞻性多中心临床试验。

研究设计与样本

  • 本综述评估了以PSMA为靶点的诊疗一体化在前列腺癌患者中的现状,讨论了目前可获得的最重要数据(多为回顾性研究)。

主要发现

  • 68Ga-PSMA PET/CT对高危PC初诊分期有意义,联合盆腔mpMR(或PET/mpMR)对患者管理影响最大;在中危PC患者中可能也有应用价值,但目前数据有限。
  • 在局部复发的二次分期中,68Ga-PSMA PET/mpMR优于PET/CT;在远处复发中,PET/CT结果等效且比PET/mpMR更快、更便宜。
  • 68Ga-PSMA PET/CT在初诊分期和二次分期中均优于18F/11C胆碱PET/CT。
  • 生化复发患者中,PET/CT阳性率与PSA升高直接相关:PSA≤0.5 ng/ml时约50%,PSA>1 ng/ml时≥90%。
  • 177Lu-PSMA配体累积活度30-50 GBq似乎临床安全,约75%患者出现生化缓解和PERCIST/RECIST缓解,5-10%患者出现口干症作为唯一显著副作用。

关键数值与推荐

  • 推荐在高危患者初诊分期时行68Ga-PSMA PET/CT联合盆腔mpMR。
  • 推荐在所有患者二次分期时行68Ga-PSMA PET/CT。
  • 推荐PSMA靶向治疗作为其他治疗方案失败后CRPC患者的有效策略。
  • 177Lu-PSMA配体累积活度30-50 GBq似乎临床安全。

临床怎么用

  • 高危PC患者初诊分期可行68Ga-PSMA PET/CT联合盆腔mpMR。
  • 所有PC患者二次分期可行68Ga-PSMA PET/CT。
  • 其他治疗方案失败后的CRPC患者可行PSMA靶向治疗。

局限性

  • 目前可获得的数据多为回顾性研究。
  • 中危PC患者中68Ga-PSMA PET/CT应用的数据目前仅有少数。
  • PSMA靶向治疗与现有治疗模式的联合需要探索。
  • 需要前瞻性多中心诊疗一体化临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA radioligand therapy (PRLT) in castration-resistant (CR)PC is assessed. The most eminent data from mostly retrospective studies currently available on theranostics of prostate cancer are discussed. The current knowledge on 68Ga-PSMA PET/CT implicates that primary staging with PET/CT is meaningful in patients with high-risk PC and that the combination with pelvic multi parametric (mp)MR (or PET/mpMR) reaches the highest impact on patient management. There may be a place for 68Ga-PSMA PET/CT in intermediate-risk PC patients as well, however, only a few data are available at the moment. In secondary staging for local recurrence, 68Ga-PSMA PET/mpMR is superior to PET/CT, whereas for distant recurrence, PET/CT has equivalent results and is faster and cheaper compared to PET/mpMR. 68Ga-PSMA PET/CT is superior to 18F / 11Choline PET/CT in primary staging as well as in secondary staging. In patients with biochemical relapse, PET/CT positivity is directly associated with prostate-specific antigen (PSA) increase and amounts to roughly 50% when PSA is raised to ≤0.5 ng/ml and to ≥90% above 1 ng/ml. Significant clinical results have so far been achieved with the subsequent use of radiolabeled PSMA ligands in the treatment of CRPC. Accumulated activities of 30 to 50 GBq of 177Lu-PSMA ligands seem to be clinically safe with biochemical response and PERCIST/RECIST response in around 75% of patients along with xerostomia in 5-10% of patients as the only notable side effect. On the basis of the current literature, we conclude that PSMA-directed theranostics do have a major clinical impact in diagnosis and therapy of PC patients. We recommend that 68Ga-PSMA PET/CT should be performed in primary staging together with pelvic mpMR in high-risk patients and in all patients for secondary staging, and that PSMA-directed therapy is a potent strategy in CRPC patients when other treatment options have failed. The combination of PSMA-directed therapy with existing therapy modalities (such as 223Ra-chloride or androgen deprivation therapy) has to be explored, and prospective clinical multicenter trials with theranostics are warranted.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 29282518. doi:10.1007/s00259-017-3882-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。